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Facial nerve palsy due to temporal bone metastasis of hepatocellular carcinoma (HCC) has rarely been reported. We 
experienced a rare case of temporal bone metastasis of HCC that initially presented as facial nerve palsy and was 
diagnosed by surgical biopsy. This patient also discovered for the first time that he had chronic hepatitis B and C infections 
due to this facial nerve palsy. Radiation therapy greatly relieved the facial pain and facial nerve palsy. This report suggests 
that hepatologists should consider metastatic HCC as a rare but possible cause of new-onset cranial neuropathy in 
patients with chronic viral hepatitis. (Korean J Hepatol 2011;17:319-322)
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INTRODUCTION
Temporal bone metastasis of hepatocellular carcinoma 
(HCC) has rarely been reported.
1 Only one case of facial 
nerve palsy due to temporal bone metastasis of HCC has 
been reported and it was detected by autopsy.
2 We 
encountered a case of metastatic HCC to the temporal region 
of the skull that initially presented as facial nerve palsy and 
was incidentally found during the diagnostic work up.
CASE REPORT
A 61-year-old man visited our hospital because of 
progressively worsening right facial pain and numbness 
over a 6-month period. The pain had developed insidiously 
and had been occurring intermittently. He could not make 
abrupt facial expressions on the right side of his face for 
seven days before he came to our hospital. He had a squeezing 
headache on the right side of his head. He had no history of 
previous illness.
On physical examination, he had paresthesia and 
hypesthesia over all territories of 3 branches of the trigeminal 
nerve, facial palsy in the right side of his face, and hearing 
loss without tinnitus in his right ear. Other cranial nerve 
examinations were normal. In nasopharyngeal magnetic 
resonance image (MRI), a 5-cm, heterogeneously enhancing 
tumor was found in T1 weighted image (Fig. 1). The tumor 
was located in the masticator space and right middle cranial 
fossa, abutting the right cavernous sinus and extending 
intracranially to the right ipsilateral infratemporal fossa. The 
tumor was hypermetabolic in positron emission tomography 
(PET) study using C-11-methionine, which suggested that 
the tumor might be a malignant lesion (Fig. 2). Bony 
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Figure 1. T1-weighted MRI of the nasopharyngeal region revealed
a 5-cm heterogeneously enhanced mass (arrow) located mainly 
in the right masticator space and middle cranial fossa, abutting 
the right cavernous sinus and with an intracranial extension to 
the right ipsilateral infratemporal fossa.
Figure 2. C-11-methionine PET revealed a hypermetabolic lesion 
(arrow) at the right temporal lobe of the brain, suggesting a 
malignant tumor.
Figure 3. Photomicrograph of the biopsy specimen showing 
cords of large neoplastic cells with oval nuclei resembling 
hepatocytes (arrow), which suggests metastasis of hepatocellular 
carcinoma (H&E stain, ×200).
Figure 4. Immunohistochemistry of the biopsy specimen with 
anti-alpha-fetoprotein antibody revealed a diffusely stained pattern
over cords of large neoplastic cells with oval nuclei resembling 
hepatocytes (arrow), which is consistent with a metastasis of 
hepatocellular carcinoma (alpha-fetoprotein, ×200).
anterior genu portion of the facial nerve, was suspected to be 
the cause of facial nerve palsy. 
The patient was admitted for surgical biopsy of the tumor. 
His laboratory findings were as follows: white blood cell 
count was 6,900 per mm
3, hemoglobin was 15.3 g/dL, 
platelet was 152,000 per mm
3, serum albumin was 3.4 g/dL, 
total bilirubin was 1.1 mg/dL, alkaline phosphatase was 
134 IU/L, aspartate aminotransferase was 97 IU/L, alanine 
aminotransferase was 192 IU/L, gamma glutamyltransferase 
was 131 IU/L, and prothrombin time evealed 1.1 international 
normalized ratio. The serologic finding revealed positive for 
hepatitis B surface antigen (HBsAg), antibody to hepatitis B 
envelop antigen (HBeAg) and antibody to hepatitis C virus 
(anti-HCV). His serum hepatitis B virus DNA level was 
97,200 IU/mL. Serum alpha-fetoprotein was 5,200 ng/mL 
and des-gamma- carboxy prothrombin was 17,268 nAU/mL. 
Endoscopic surgical biopsy with sphenoidotomy via the 
right nasal cavity was performed by an otolaryngologist. 
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Figure 5. Abdominal CT revealed a 5-cm fat-containing, ill-defined, and subtly enhanced mass lesion in segment 8 (arrow) in the 
cirrhotic liver. (A) precontrast, (B) arterial phase, (C) portal phase.
to the inferolateral wall through the destroyed bone. The 
pathological finding was consistent with metastatic HCC 
(Fig. 3). Immunohistochemical findings of the biopsy 
specimen revealed positive staining for alpha-fetoprotein, 
which was also consistent with metastatic HCC (Fig. 4). 
Other metastases were found in lumbar spines (L1, L2) and 
right femur in bone scan. Radiation therapy was performed 
for the tumor in the masticator space and right middle cranial 
fossa and for the metastatic lesions in lumbar spines and 
right femur. After radiation therapy was finished, his facial 
pain subsided significantly and his facial nerve palsy was 
partially relieved. Facial pain did not occur again and facial 
nerve palsy did not progress until 7 months later.
To evaluate the primary HCC in liver, abdominal computed 
tomography (CT) was performed. A 5-cm-sized, fat-containing, 
ill-defined and subtly enhanced mass lesion was found in 
segment 8 in the cirrhotic liver (Fig. 5). Although repeated 
transarterial chemoembolization (TACE) was tried 3 times 
over 7 months to treat this tumor, only marginal lipiodol 
uptake was observed with each TACE. 
Seven months after initial diagnosis of metastatic HCC, 
back pain occurred over 2 weeks. Bone scan and spinal MRI 
showed progressed spinal metastasis. As no therapy remained 
for the multiple spinal metastases, the patient was transferred 
to a hospital near his home for supportive care.
DISCUSSION
Temporal bone metastasis of HCC has rarely been 
reported.
2 Though HCC commonly metastasizes to bone, 
metastasis of HCC to skull is uncommon.
3 Facial palsy due 
to HCC was reported once in an advanced cirrhotic patient 
after autopsy.
2 Therefore, our report might be the first case 
report of metastatic HCC to the temporal region of skull 
involving the facial and trigeminal nerve, as confirmed 
by surgical biopsy.
2 Metastatic HCC was diagnosed by 
surgical biopsy in this case. Even if HCC had been found in 
liver prior to performing the biopsy of temporal metastatic 
lesion, tissue confirmation of the lesion in temporal area 
would have been done for proper management because exact 
diagnosis was needed for proper management and because 
the lesion could have been an isolated double primary tumor 
such as schwannoma. 
As far as temporal bone metastasis of malignant tumors, 
bilateral temporal bone involvements are more common 
than unilateral involvement, but in this patient and the 
previous autopsy-proven case of temporal bone metastasis 
of HCC, the lesions were only on the right side.
2 Hearing 
loss without vestibular manifestation was reported as the 
most common symptom of temporal bone metastases in a 
retrospective study of 47 autopsy cases, which was 
consistent with this case.
4 In the case of facial palsy 
secondary to metastasis, involvement of other cranial nerves 
was more common than involvement of the facial nerve 
alone, which was also consistent with this case.
4 Radiological 
investigation is strongly recommended if the facial nerve 
palsy is clinically associated with other neurological signs.
5,6 
Bone and brain metastases of HCC have been treated with 
palliative radiation therapy and pain relief has been observed 
in about 78% of patients, suggesting good responsiveness to 
radiation.
7 Therefore, we performed radiation therapy for 
the metastatic lesion in the temporal area and the pain 
completely subsided. Our case may suggest that temporal 
bone metastasis of HCC is also a very good indication for 
radiation therapy.
 
Hepatic dysfunction is known to be the main prognostic 
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factor in patients with HCC, even in patients with extrahepatic 
metastasis. The major survival factor for our patient might 
also be the progression of hepatic dysfunction.
8,9 Sorafenib 
treatment might have been considered in this patient because 
the intrahepatic HCC progressed despite repeated TACE; 
however, sorafenib was not available during our caring for 
him.
10,11 
In summary, we encountered a very rare case of histo-
logically proven temporal bone metastasis of HCC that was 
found during the evaluation of a patient who presented with 
trigeminal, facial and auditory nerve dysfunction and who 
was positive for both HBsAg and anti-HCV but without 
previous history of illness. Our case suggests that hepatolo-
gists may consider metastatic HCC as a rare cause of new 
onset cranial nerve palsy in patients with chronic viral 
hepatitis, and radiation therapy may be considered for the 
treatment of temporal bone metastasis of HCC with cranial 
nerve involvement.
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